Disease · MONDO_0005047
Comparisons in its trials38
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 38
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Single Injection of 150 µg SCH 900962/MK-8962 vs Daily 300 IU recFSH: Number of Participants Who Cancelled the Cycle Due to a (Serious) Adverse Event | 5 of 692 | 6 of 698 | 1,390 | NCT01144416 | Trial comparisons |
| Single Injection of 150 µg SCH 900962/MK-8962 vs Daily 300 IU recFSH: Number of Participants With Moderate or Severe Ovarian Hyperstimulation Syndrome (OHSS) | 5 of 692 | 10 of 698 | 1,390 | NCT01144416 | Trial comparisons |
| FE 999049 vs GONAL-F: serious adverse events | 16 of 665 | 10 of 661 | 1,326 | NCT01956110 | Trial comparisons |
| Pergoveris vs GONAL-f: serious adverse events | 8 of 462 | 17 of 477 | 939 | NCT02047227 | Trial comparisons |
| Highly Purified Menotrophin vs Recombinant FSH: serious adverse events | 5 of 374 | 7 of 375 | 749 | NCT00884221 | Trial comparisons |
| FE 999049 (Follitropin Delta) vs Placebo: deaths from any cause | 0 of 525 | 0 of 53 | 578 | NCT03740737 | Trial comparisons |
| FE 999049 (Follitropin Delta) vs Placebo: serious adverse events | 4 of 525 | 0 of 53 | 578 | NCT03740737 | Trial comparisons |
| MENOPUR Liquid vs MENOPUR Powder: Ongoing Pregnancy Rate | 91 of 202 | 85 of 199 | 401 | NCT04163458 | Trial comparisons |
| MENOPUR Liquid vs MENOPUR Powder: Positive Beta Human Chorionic Gonadotropin (βhCG) Rate | 113 of 202 | 110 of 199 | 401 | NCT04163458 | Trial comparisons |
| MENOPUR Liquid vs MENOPUR Powder: Number of Participants With Potential Technical Malfunctions of the Administration Pen | 1 of 202 | 1 of 199 | 401 | NCT04163458 | Trial comparisons |
| MENOPUR Liquid vs MENOPUR Powder: deaths from any cause | 0 of 202 | 0 of 199 | 401 | NCT04163458 | Trial comparisons |
| MENOPUR Liquid vs MENOPUR Powder: Clinical Pregnancy Rate | 94 of 202 | 88 of 199 | 401 | NCT04163458 | Trial comparisons |
| MENOPUR Liquid vs MENOPUR Powder: serious adverse events | 4 of 202 | 2 of 199 | 401 | NCT04163458 | Trial comparisons |
| 100 μg Corifollitropin Alfa vs 150 IU recFSH: serious adverse events | 20 of 268 | 9 of 129 | 397 | NCT00702845 | Trial comparisons |
| AFOLIA-150 (Follitropin Alfa) vs Gonal-f® (Follitropin Alfa): Number of Patients With Good Response | 217 of 249 | 107 of 123 | 372 | NCT01121666 | Trial comparisons |
| AFOLIA-150 (Follitropin Alfa) vs Gonal-f® (Follitropin Alfa): serious adverse events | 12 of 249 | 3 of 123 | 372 | NCT01121666 | Trial comparisons |
| FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta): Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Hematology Parameters at End-of-stimulation | 0 of 170 | 0 of 177 | 347 | NCT03228680 | Trial comparisons |
| FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta): deaths from any cause | 0 of 170 | 0 of 177 | 347 | NCT03228680 | Trial comparisons |
| FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta): Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Clinical Chemistry Parameters at End-of-trial | 0 of 170 | 0 of 177 | 347 | NCT03228680 | Trial comparisons |
| FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta): serious adverse events | 0 of 170 | 2 of 177 | 347 | NCT03228680 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005047/comparisons